Founded in 2001, Beijing Jenkem Technology Co., Ltd (“Beijing Jenkem”, or the “Company”) specializes exclusively in the research and development and manufacturing of high quality polyethylene glycol (PEG) products and derivatives, and related customized synthesis and PEGylation services. It caters to the PEGylation needs of the pharmaceutical, biotechnology, medical device and diagnostics, and emerging chemical specialty markets, from laboratory scale through to commercial scale. The R&D capability and production capacity of the Company is ranked No. 3 in the world, which gives the Company overwhelming competitive advantages over its peers in China.

With the dominant advantages in the PEG material industry, the Company expanded its business vertically and began to provide innovative applications based on PEG materials, i.e. the R&D service of PEG based medicines and medical devices.

For the fiscal year 2015, the Company earned revenue in the sum of RMB 71.6m and gained a rapid 42% y-o-y sales growth. Its net profits increased by more than 85% from the previous year and reached RMB 22m.

The Company has partnered with numerous large domestic and international pharmaceutical companies to develop new drugs and a number of projects have been in clinic trials with very promising results. Due to the difficulty and complexity for the large drug companies to change its supplier after obtaining CFDA or FDA approvals, the Company will enjoy secured and long-term revenue growth once the drugs go to market.

Beijing Jenkem plans to set up a new manufacturing base in Liaoning Province aiming to take full advantage of low rental costs and closer raw material supplies.

TCC Capital partnered with Tsinghua-backed VC funds and invested in Beijing Jenkem in the second half of 2015. With TCC Capital’s assistance, the company is currently in its IPO process in domestic A-share ChiNext capital market.